Position in APGE
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$45,382,528
+$7,375,405 QoQ
Shares Held
539,177
+7.1% QoQ
Ownership
0.712%
of shares outstanding
% of Portfolio
0.20%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2024
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in APGE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Polar Capital Holdings Plc holds $3,774,805,029 across 41 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ELVN |
Enliven Therapeutics, Inc.
|
6,430,636 | $326,354,777 | |
| 2 | XENE |
Xenon Pharmaceuticals Inc.
|
4,570,556 | $275,878,760 | |
| 3 | CYTK |
Cytokinetics Inc
|
2,253,649 | $191,988,358 | |
| 4 | RYTM |
Rhythm Pharmaceuticals, Inc.
|
1,663,632 | $184,713,060 | |
| 5 | ARQT |
Arcutis Biotherapeutics, Inc.
|
6,606,945 | $173,234,097 | |
| 6 | ASND |
Ascendis Pharma A/S
|
616,908 | $164,541,701 | |
| 7 | BBIO |
BridgeBio Pharma, Inc.
|
2,063,609 | $153,697,598 | |
| 8 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
482,751 | $145,322,533 |
All Filings in APGE
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $45,382,528 | 539,177 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $38,007,123 | 503,539 | Shares | Defined | 2026-02-17 | |
| 2025-09-30 | $20,822,254 | 524,094 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $21,497,850 | 495,000 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $20,548,000 | 550,000 | Shares | Defined | 2025-05-15 | |
| 2024-06-30 | $9,837,500 | 250,000 | Shares | Defined | 2024-08-14 | |
| No filing history on record for this holder in this stock. | ||||||